Purpose: CD137 is a T-and NK-cell costimulatory receptor involved in consolidating
immunologic responses. The potent CD137 agonist urelumab has shown clinical promise as …

The costimulatory receptor CD137 (also known as TNFRSF9 or 4-1BB) sustains effective
cytotoxic T-cell responses. Agonistic anti-CD137 cancer immunotherapies are being …

Background On the basis of efficacy in mouse tumor models, multiple CD137 (4-1BB)
agonist agents are being preclinically and clinically developed. The costimulatory molecule …

Background CD137 (4-1BB) represents a costimulatory pathway that promotes T, NK, and
dendritic cell effector functions favorable for antitumor immunity. The extracellular domain of …

CD137 (4‐1BB, TNFRSF9), an inducible T‐cell costimulatory receptor, is expressed on
activated T cells, activated NK cells, Treg cells, and several innate immune cells, including …

Twenty-five years ago, we reported that agonist anti-CD137 monoclonal antibodies
eradicated transplanted mouse tumors because of enhanced CD8+ T-cell antitumor …

TPS3107 Background: CD137 (4-1BB) is a costimulatory molecule that belongs to the TNF
superfamily. It is upregulated on activated lymphocytes, NK cells and dendritic cells and …

ABSTRACT CD137 (4-1BB) is a surface glycoprotein that belongs to the tumour necrosis
factor receptor family (TNFRSF9). Its expression is induced on activation on a number of …

Costimulation via CD137 (4-1BB) enhances antitumor immunity mediated by cytotoxic T
lymphocytes. Anti-CD137 agonist antibodies elicit mild liver inflammation in mice, and the …

Abstract CD137 (4-1BB) is an important costimulatory ligand and a potent stimulator of T-cell
responses. It has been used therapeutically to stimulate immunity against several solid …